These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 2553900)

  • 1. Does the duration of action of angiotensin converting enzyme inhibitors affect their safety and adverse effects?
    Frank GJ
    J Hypertens Suppl; 1989 Sep; 7(5):S17-22. PubMed ID: 2553900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety and tolerability of quinapril.
    Knapp LE; Frank GJ; McLain R; Rieger MM; Posvar E; Singer R
    J Cardiovasc Pharmacol; 1990; 15 Suppl 2():S47-55. PubMed ID: 1691407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ACE inhibitors: review of four new agents.
    Binder SB
    Am Fam Physician; 1993 Oct; 48(5):851-7. PubMed ID: 8213415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety profile of quinapril: is there a difference among ACE inhibitors?
    Canter D; Frank GJ; Knapp LE; McLain RW
    Clin Cardiol; 1990 Jun; 13(6 Suppl 7):VII39-42. PubMed ID: 2189620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Renal side effects of angiotensin converting enzyme inhibitors].
    Schmidt A; Mayer G
    Wien Med Wochenschr; 1996; 146(16):454-6. PubMed ID: 9036683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quinapril. A reappraisal of its pharmacology and therapeutic efficacy in cardiovascular disorders.
    Plosker GL; Sorkin EM
    Drugs; 1994 Aug; 48(2):227-52. PubMed ID: 7527326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin converting enzyme inhibitor-induced renal dysfunction: recommendations for prevention.
    Cooke HM; De Besse A
    Int J Clin Pharmacol Ther; 1994 Feb; 32(2):65-70. PubMed ID: 8004361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Side effects of vasodilator therapy in heart failure: risk of hypotension with ACE inhibitors].
    Kromer EP; Elsner D; Riegger GA
    Z Kardiol; 1991; 80 Suppl 2():11-5. PubMed ID: 2024538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin converting enzyme inhibitors and the otolaryngologist.
    Cruickshank HE
    Clin Otolaryngol Allied Sci; 1995 Jun; 20(3):189-91. PubMed ID: 7554324
    [No Abstract]   [Full Text] [Related]  

  • 11. [Angiotensin-converting enzyme inhibition: side effects and risks].
    Schilling H; Scheler F
    Z Kardiol; 1988; 77 Suppl 3():47-54. PubMed ID: 2850687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A postmarketing surveillance evaluation of quinapril in 3742 Canadian hypertensive patients: the ACCEPT Study. Accupril Canadian Clinical Evaluation and Patient Teaching.
    Larochelle P; Haynes B; Maron N; Dugas S
    Clin Ther; 1994; 16(5):838-53. PubMed ID: 7859244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quinapril: a new second-generation ACE inhibitor.
    Cetnarowski-Cropp AB
    DICP; 1991 May; 25(5):499-504. PubMed ID: 2068835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of captopril and enalapril in patients with severe chronic heart failure.
    Packer M; Lee WH; Yushak M; Medina N
    N Engl J Med; 1986 Oct; 315(14):847-53. PubMed ID: 3018566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Undesirable effects and interaction to angiotensin converting enzyme inhibitors therapy].
    Ionescu SD; Sandru V; Leuciuc E; Manea P; Burdujan A; Tovarniţchi S; Cosovanu A
    Rev Med Chir Soc Med Nat Iasi; 2002; 106(1):128-31. PubMed ID: 12635373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacology of quinapril in healthy volunteers and in patients with hypertension and congestive heart failure.
    Sedman AJ; Posvar E
    Angiology; 1989 Apr; 40(4 Pt 2):360-9. PubMed ID: 2539762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse effects of converting-enzyme inhibition in patients with severe congestive heart failure: pathophysiology and management.
    Packer M; Kessler PD; Gottlieb SS
    Postgrad Med J; 1986; 62 Suppl 1():179-82. PubMed ID: 3022272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinctive properties of perindopril among converting enzyme inhibitors in congestive heart failure.
    Sami MH
    Can J Cardiol; 1994 Nov; 10 Suppl D():13D-16D. PubMed ID: 7954033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The current status of angiotensin converting enzyme inhibitors in the management of patients with chronic heart failure.
    Packer M; Kukin ML; Neuberg GW; Pinsky DJ; Penn J; Abittan MH
    J Hypertens Suppl; 1989 Sep; 7(5):S33-6. PubMed ID: 2681605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview: the role of angiotensin-converting enzyme inhibitors in cardiovascular therapy.
    Abrams WB; Davies RO; Ferguson RK
    Fed Proc; 1984 Apr; 43(5):1314-21. PubMed ID: 6323221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.